부산대학교 도서관

Welling, Richard, MD

Journal of Vascular Surgery. 18(4):726-727

Kruit WHJ; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AMM; Louahed J; Lehmann FF; Brichard VG; Keilholz U

Journal of Clinical Oncology. 31:2413-2420

Kivelä, T; Suciu, S; Hansson, J; Kruit, WHJ; Vuoristo, MS; Kloke, O; Gore, M; Hahka-Kemppinen, M; Parvinen, LM; Kumpulainen, E

EUROPEAN JOURNAL OF CANCER. 39(8):1115-1120

Marchand, M; Punt, CJA; Aamdal, S; Escudier, B; Kruit, WHJ; Keilholz, U; Håkansson, Leif; van Baren, N; Humblet, Y; Mulders, P; Avril, M-F; Eggermont, AMM; Scheibenbogen, C; Uiters, J; Wanders, J; Delire, M; Boon, T; Stoter, G

European Journal of Cancer. 39(1):70-77

van Dijk EHC; Department of Ophthalmology, Leiden University Medical Centre, Leiden, the Netherlands.; Kruit WHJ; Department of Internal Oncology, Erasmus University Medical Centre-Daniel den Hoed Cancer Centre, Rotterdam, the Netherlands.; Jager MJ; Department of Ophthalmology, Leiden University Medical Centre, Leiden, the Netherlands.; Luyten GPM; Department of Ophthalmology, Leiden University Medical Centre, Leiden, the Netherlands.; Vingerling JR; Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, the Netherlands.; Boon CJF; Department of Ophthalmology, Leiden University Medical Centre, Leiden, the Netherlands.; Department of Ophthalmology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101468102 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1755-3768 (Electronic) Linking ISSN: 1755375X NLM ISO Abbreviation: Acta Ophthalmol Subsets: MEDLINE

Kloth JSL; Pagani A; Verboom MC; Malovini A; Napolitano C; Kruit WHJ; Sleijfer S; Steeghs N; Zambelli A; Mathijssen RHJ

Journal of Clinical Oncology. 32:2590-2590

Leeneman B; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam.; Blommestein HM; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam.; Coupé VMH; Department of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam.; Hendriks MP; Department of Internal Medicine, Northwest Clinics, Alkmaar.; Kruit WHJ; Department for Medical Oncology, Erasmus MC Cancer Institute, Rotterdam.; Plaisier PW; Department of Surgical Oncology, Albert Schweitzer Hospital, Dordrecht.; van Ruth S; Department of Dermatology, Tergooi, Hilversum.; Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Breda.; Wouters MWJM; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam.; Franken MG; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam.; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.; Uyl-de Groot CA; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam.; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.

Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9109623 Publication Model: Print Cited Medium: Internet ISSN: 1473-5636 (Electronic) Linking ISSN: 09608931 NLM ISO Abbreviation: Melanoma Res Subsets: MEDLINE

Jochems A; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands. a.jochems@lumc.nl.; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands. a.jochems@lumc.nl.; van der Kooij MK; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands.; Fiocco M; Medical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands.; Mathematical Institute Leiden University, Niels Bohrweg 1, 2333 CA Leiden, The Netherlands.; Schouwenburg MG; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands.; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.; Aarts MJ; Department of Medical Oncology, Maastricht University Medical Centre, P. Debyelaan 25, 6202 AZ Maastricht, The Netherlands.; van Akkooi AC; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre, 6130 MB Sittard-Geleen, The Netherlands.; Blank CU; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; van den Eertwegh AJM; Department of Medical Oncology, VU Medical Centre, de Boelelaan 1117, 1081 HZ Amsterdam, The Netherlands.; Franken MG; Department of Health Technology Assessment, Institute for Medical Technology Assessment and Erasmus School of Health Policy & Management, Erasmus University, Burgemeester Oudlaan 50, 3000 DR Rotterdam, The Netherlands.; de Groot JB; Department of Medical Oncology, Isala Oncological Center, 8000 GK Zwolle, The Netherlands.; Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.; Koornstra RH; Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6500 HB Nijmegen, The Netherlands.; Kruit WHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Molewaterplein 40, 3000 CA Rotterdam, The Netherlands.; Louwman M; Netherlands Comprehensive Cancer Organisation, PO Box 19079, 3501 DB Utrecht, The Netherlands.; Piersma D; Department of Medical Oncology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The Netherlands.; van Rijn RS; Department of Medical Oncology, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, The Netherlands.; Suijkerbuijk KPM; Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.; Ten Tije AJ; Department of Medical Oncology, Amphia Ziekenhuis, Langendijk 175, 4819 EV Breda, The Netherlands.; Vreugdenhil G; Department of Medical Oncology, Maxima Medisch Centrum, de Run 4600, 5500 MB Veldhoven, The Netherlands.; Wouters MWJM; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; van Zeijl MCT; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands.; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.; van der Hoeven KJM; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands.; Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6500 HB Nijmegen, The Netherlands.; Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

Franken MG; Institute for Medical Technology Assessment.; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University.; Leeneman B; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University.; Jochems A; Dutch Institute for Clinical Auditing.; Department of Medical Oncology, Leiden University Medical Center, Leiden.; Schouwenburg MG; Dutch Institute for Clinical Auditing.; Department of Medical Oncology, Leiden University Medical Center, Leiden.; Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center, Maastricht.; van Akkooi ACJ; Departments of Surgical Oncology.; van den Berkmortel FWPJ; Department of Internal Medicine, Zuyderland Medical Center Geleen-Heerlen, Sittard-Geleen.; van den Eertwegh AJM; Dutch Institute for Clinical Auditing.; Department of Medical Oncology, VU University Medical Center, Amsterdam.; de Groot JWB; Department of Medical Oncology, Isala Oncological Center, Zwolle.; van der Hoeven KJM; Dutch Institute for Clinical Auditing.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen.; Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen.; Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden.; Koornstra R; Department of Medical Oncology, Radboud University Medical Center, Nijmegen.; Kruit WHJ; Department of Medical Oncology, ErasmusMC Cancer Institute, Rotterdam.; Louwman MWJ; Netherlands Comprehensive Cancer Organisation.; Piersma D; Department of Internal Medicine/Oncology, Medisch Spectrum Twente, Enschede.; van Rijn RS; Department of Internal Medicine/Oncology, Medical Center Leeuwarden, Leeuwarden.; Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht.; Ten Tije AJ; Department of Internal Medicine/Oncology, Amphia Hospital, Breda.; Vreugdenhil G; Department of Internal Medicine/Oncology, Maxima Medical Center, Veldhoven, The Netherlands.; Wouters MWJM; Dutch Institute for Clinical Auditing.; Departments of Surgical Oncology.; van Zeijl M; Dutch Institute for Clinical Auditing.; Haanen JBAG; Dutch Institute for Clinical Auditing.; Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek.; Uyl-de Groot CA; Institute for Medical Technology Assessment.; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University.

Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE

Dreno B; Department of Dermatooncology, Hotel Dieu Nantes University Hospital, Nantes, France.; Thompson JF; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Smithers BM; Queensland Melanoma Project, Discipline of Surgery, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.; Santinami M; Melanoma Sarcoma Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.; Jouary T; Service d'Oncologie Médicale, Hôpital François Mitterrand, Pau, France.; Gutzmer R; Skin Cancer Center Hannover, Department of Dermatology, Hannover Medical School, Hannover, Germany.; Levchenko E; Petrov Research Institute of Oncology, St Petersburg, Russia.; Rutkowski P; Department of Soft Tissue, Bone Sarcoma, and Melanoma, Maria Sklodowska-Curie Institute, Oncology Center, Warsaw, Poland.; Grob JJ; Department of Dermatology and Skin Cancers, La Timone APHM Hospital, Aix-Marseille University, Marseille, France.; Korovin S; Department of Skin and Soft Tissue Tumours, National Cancer Institute, Kiev, Ukraine.; Drucis K; Swissmed Centrum Zdrowia, Gdansk, Poland; Department of Surgical Oncology, Gdansk Medical University, Gdansk, Poland.; Grange F; Dermatology Department, Hôpital Robert Debré, Université de Reims Champagne-Ardenne, Reims, France.; Machet L; Department of Dermatology, Centre Hospitalier Universitaire, Tours, France; UFR de Médecine, Université François-Rabelais, Tours, France.; Hersey P; Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, Sydney, NSW, Australia.; Krajsova I; Dermato-oncology Department, General University Hospital, Prague, Czech Republic.; Testori A; Columbus Clinic Center, Milan, Italy.; Conry R; Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.; Guillot B; Département de Dermatologie, Centre Hospitalier Universitaire, Hôpital Saint-Éloi, Montpellier, France.; Kruit WHJ; Department of Medical Oncology, Erasmus MC Cancer institute, Rotterdam, Netherlands.; Demidov L; Cancer Research Center, Moscow, Russia.; Thompson JA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA.; Bondarenko I; Department of Oncology and Medical Radiology, Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine.; Jaroszek J; Centrum Medyczne Bieńkowski, Klinika Chirurgii Plastycznej, Bydgoszcz, Poland; Department of Oncological Surgery, Oncology Center, Bydgoszcz, Poland.; Puig S; Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain.; Cinat G; Instituto de Oncología Ángel H Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina.; Hauschild A; Department of Dermatology, Venereology, and Allergology, University Hospital Schleswig-Holstein, Kiel, Germany.; Goeman JJ; Medical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands.; van Houwelingen HC; Medical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands.; Ulloa-Montoya F; GlaxoSmithKline, Rixensart, Belgium. Electronic address: fernando.x.ulloa-montoya@GSK.com.; Callegaro A; GlaxoSmithKline, Rixensart, Belgium.; Dizier B; GlaxoSmithKline, Rixensart, Belgium; Immunology Translational Medicine, UCB, Brussels, Belgium.; Spiessens B; GlaxoSmithKline, Rixensart, Belgium; Biostatistics Department, Janssen Research & Development, Beerse, Belgium.; Debois M; GlaxoSmithKline, Rixensart, Belgium.; Brichard VG; GlaxoSmithKline, Rixensart, Belgium; ViaNova Biosciences, Brussels, Belgium.; Louahed J; GlaxoSmithKline, Rixensart, Belgium.; Therasse P; GlaxoSmithKline, Rixensart, Belgium; Laboratoires Servier, Paris, France.; Debruyne C; GlaxoSmithKline, Rixensart, Belgium; University Hospitals Leuven, Leuven, Belgium.; Kirkwood JM; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

Jochems A; Department of Medical Oncology, Leiden University Medical Center.; Dutch Institute for Clinical Auditing, Leiden.; Leeneman B; Department of Health Technology Assessment, Erasmus School of Health Policy & Management.; Franken MG; Institute for Medical Technology Assessment, Erasmus University Rotterdam.; Schouwenburg MG; Department of Medical Oncology, Leiden University Medical Center.; Dutch Institute for Clinical Auditing, Leiden.; Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center, Maastricht.; van Akkooi ACJ; Departments of Surgical Oncology.; van den Berkmortel FWPJ; Department of Internal Medicine, Zuyderland Medical Center Geleen, Heerlen.; van den Eertwegh AJM; Dutch Institute for Clinical Auditing, Leiden.; Department of Medical Oncology, VU University Medical Center, Amsterdam.; Groenewegen G; Department of Medical Oncology, University Medical Center Utrecht.; de Groot JWB; Department of Medical Oncology, Isala, Zwolle.; Haanen JBAG; Dutch Institute for Clinical Auditing, Leiden.; Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital.; Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, Groningen.; Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center.; Koornstra RH; Department of Medical Oncology, Radboud University Medical Center, Nijmegen.; Kruit WHJ; Department for Medical Oncology, Erasmus MC Cancer Institute, Rotterdam.; Louwman MWJ; Netherlands Comprehensive Cancer Organisation, Utrecht.; Piersma D; Department of Internal Medicine, Medical Spectrum Twente, Enschede.; van Rijn RS; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden.; Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Breda.; Vreugdenhil G; Department of Internal Medicine, Maxima Medical Center, Veldhoven, The Netherlands.; Wouters MWJM; Dutch Institute for Clinical Auditing, Leiden.; Departments of Surgical Oncology.; Uyl-de Groot CA; Department of Health Technology Assessment, Erasmus School of Health Policy & Management.; Institute for Medical Technology Assessment, Erasmus University Rotterdam.; van der Hoeven KJM; Dutch Institute for Clinical Auditing, Leiden.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen.

Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE

Sleijfer, S; Bannink, M; Van Gool, AR; Kruit, WHJ; Stoter, G

PHARMACY WORLD & SCIENCE; DEC 2005, 27 6, p423-p431, 9p.

Kruit, WHJ; van Ojik, HH; Brichard, VG; Escudier, B; Dorval, T; Dreno, B; Patel, P; van Baren, N; Avril, MF; Piperno, S; Khammari, A; Stas, M; Ritter, G; Lethe, B; Godelaine, D; Brasseur, F; Zhang, Y; van der Bruggen, P; Boon, T; Eggermont, AMM; Marchand, M

INTERNATIONAL JOURNAL OF CANCER; NOV 20 2005, 117 4, p596-p604, 9p.

Bannink, M; Kruit, WHJ; Van Gool, AR; Mulder, PGH; Sleijfer, S; Eggermont, AMM; Stoter, G; Fekkes, D

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY; JAN 2005, 29 1, p109-p114, 6p.

Van Gool, AR; Fekkes, D; Kruit, WHJ; Mulder, PGH; Ten Hagen, TLM; Bannink, M; Maes, M; Eggermont, AMM

PSYCHIATRY RESEARCH; JUL 15 2003, 119 1-2, p125-p132, 8p.

Portielje, JEA; Kruit, WHJ; Eerenberg, AJM; Schuler, M; Sparreboom, A; Lamers, CHJ; Gratama, JW; Stoter, G; Huber, C; Hack, CE

CANCER IMMUNOLOGY IMMUNOTHERAPY; JAN 2005, 54 1, p37-p43, 7p.

Sleijfer, S; Kruit, WHJ; Stoter, G

EUROPEAN JOURNAL OF CANCER; NOV 2004, 40 16, p2377-p2382, 6p.

Kruit, WHJ; Stoter, G; Klijn, JGM

ANTI-CANCER DRUGS; OCT 2004, 15 9, p843-p847, 5p.

de Wit, R; Kruit, WHJ; Stoter, G; de Boer, M; Kerger, J; Verweij, J; Kruit, W H

British Journal of Cancer; Nov1998, Vol. 78 Issue 10, p1342-1345, 4p

Van Gool, AR; Van Ojik, HH; Kruit, WHJ; Mulder, PGH; Fekkes, D; Bannink, M; Scharpe, S; Stoter, G; Eggermont, AMM; Maes, M; Verkerk, R

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH; JUL 2004, 24 7, p411-p415, 5p.